Biogen, Elan retest MS drug, see FDA action by June
March 29, 2006
CHICAGO (Reuters) – Biogen Idec and Elan Corp said on
Wednesday they have restarted a safety trial of its multiple
sclerosis drug Tysabri, which the drugmakers recalled from the
market after reports of rare brain infection were linked to the
drug.
A U.S. Food and Drug Administration panel earlier this
month recommended the drug be returned to the market, with
mandatory controls for risks and new cases of the fatal side
effect, linked to two deaths.
The companies expect an action by the FDA by June 28, 2006.
Source: reuters